Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial

Cancer Science

Volumn 106, Issue 9, 2015, Pages 1212-1218

  Ursu, Renata ^a   Taillibert, Sophie ^b   Banissi, Claire ^a   Vicaut, Eric ^c   Bailon, Olivier ^a   Le Rhun, Emilie ^d   Guillamo, Jean Sebastien ^e   Psimaras, Dimitri ^b   Tibi, Annick ^f   Sacko, Adama ^a,g   Marantidou, Athina ^a,g   Belin, Catherine ^a   Carpentier, Antoine F ^a,g  

^a AVICENNE HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Department of Medical Oncology   (France)

^e CHU CÔTE DE NACRE   (France)

^f Etablissement Pharmaceutique de l'Assistance Publique Hôpitaux de Paris Agence Générale des Equipements et Produits de Santé   (France)

^g UNIVERSITÉ PARIS 13   (France)

Author keywords

CpG ODN; Immunotherapy; Neoplastic meningitis; Phase I; TLR 9

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLOBAZAM; CPG 28; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LOMUSTINE; PEMETREXED; PREDNISOLONE; STEROID; TOLL LIKE RECEPTOR AGONIST; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 9;

ADULT; ADVERSE OUTCOME; ANEMIA; ARACHNOIDITIS; ARTICLE; BRAIN HEMATOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; EPENDYMOMA; ERYTHEMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; KARNOFSKY PERFORMANCE STATUS; LUNG CARCINOMA; LYMPHOCYTOPENIA; MALE; MELANOCYTOSIS; MELANOMA; MENINGITIS; MIDDLE AGED; NEOPLASTIC MENINGITIS; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE; THROMBOCYTOPENIA; AGED; AGONISTS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MENINGITIS; MIDDLE AGED; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; YOUNG ADULT;

EID: 84942192979     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12724     Document Type: Article

References (21)

1. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastasis in solid tumors. Surg Neurol Int 2013; 4 (Suppl 4): S265-88.
2. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27: 460-71.
3. Takeshita S, Takeshita F, Haddad DE, Janabi N, Klinman DM. Activation of microglia and astrocytes by CpG oligodeoxynucleotides. NeuroReport 2001; 12: 3029-32.
4. Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 2001; 124 (Pt 3): 480-92.
5. Wang C, Cao S, Yan Y et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010; 10: 415.
6. Meng Y, Kujas M, Marie Y et al. Expression of TLR9 within human glioblastoma. J Neurooncol 2008; 88: 19-25.
7. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-32.
8. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000; 6: 2469-73.
9. Carpentier A, Laigle-Donadey F, Zohar S et al. Phase 1 trial of CpG ODN for patients with recurrent glioblastoma. Neuro Oncol 2006; 8: 60-6.
10. Carpentier A, Metellus P, Ursu R et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010; 12: 401-8.
11. Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-6.
12. Pashenkov M, Goëss G, Wagner C et al. Phase II trial of a toll-like receptor 9 oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716-24.
13. Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31: 520-7.
14. Link BK, Ballas ZK, Weisdorf D et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin's lymphoma. J Immunother 2006; 29: 558-68.
15. Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol 2012; 746: 95-108.
16. Vicari AP, Schmalbach T, Lekstrom-Himes J et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007; 12: 741-51.
17. Weber JS, Zarour H, Redman B et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 2009; 115: 3944-54.
18. Yamada K, Nakao M, Fukuyama C et al. Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci 2010; 101: 188-95.
19. Groves MD, DeGroot J, Tremont I et al. A pilot study of systemically administered bevacizumab in patients with neoplastic meningitis/imaging, clinical, CSF, and biomarker outcomes (Abstract). Neuro Oncol 2011; 13: iii85-91.
20. Terme M, Pernot S, Marcheteau E et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. J Cancer Res 2013; 73: 539-49.
21. Banissi C, Maubant S, Rancic M, Carpentier AF. Combination of peritumoral administration of CpG-ODN with immunization against VEGF for treatement of malignant glioma (Abstract). Neuro Oncol 2012; 14 (Suppl 3): iii1-94.